USA Rare Earth Enters Definitive Agreements for Strategic Investment in Carester, Strengthening its European Rare Earth Partnership

USA Rare Earth (USAR) entered definitive agreements to acquire strategic minority stakes of ~13.6% each in France’s Carester, with InfraVia (Critical Metals Fund, backed by the French State as an anchor investor) taking a similar stake. The deal strengthens USAR/LCM Europe’s access to Carester’s Caremag oxide output and Carester’s access to USAR feedstock, with Caremag commissioning targeted for Q4 2026 and planned capacity of 800 tpa NdPr, 500 tpa Dy, and 100 tpa Tb oxides (Dy/Tb ~15% of current world production). Funding is expected in Q3 2026 and is primarily intended to support Carester’s growth (including R&D and working capital), while financing is also supported by French C3IV credits (up to 45% of eligible capex, up to €130m) and potential state-backed guarantees for commercial debt.

Analysis

This is more valuable as a strategic de-risking event than as near-term earnings accretion. For USAR, the real mechanism is not the minority stake itself; it is control over scarce heavy-rare-earth separation capacity outside China, which can strengthen negotiating leverage with OEMs, defense suppliers, and European industrial buyers before the underlying projects even produce cash flow. The second-order winner is the Europe-focused rare-earth supply chain: equipment vendors, project financiers, and downstream magnet customers gain a credible non-China sourcing path, while less integrated juniors lose relative scarcity premium if investors start assigning value to execution rather than resource size.

The market is likely to overprice the announcement in the next few sessions and underprice the funding/ramp risk over the next 6-18 months. The key catalyst chain is funding close in Q3, then evidence that construction, commissioning, and offtake are synchronized; any slip turns this back into a capital-intensive story with dilution risk. The main falsifier is a delay in late-2026 commissioning or a need for incremental equity at unfavorable terms, which would compress the current strategic multiple quickly.

Contrarian view: consensus will probably read this as proof that Western rare-earth infrastructure is finally investable, but the economics still hinge on heavy-rare-earth pricing staying firm and on process yields at scale. If the market gets enthusiastic, USAR may be the best expression only as a tactical long on pullbacks, not a core long until the financing stack and commercial throughput are visible. TMRC remains the cleaner way to express skepticism on monetization timing if investors start extrapolating too far from the Round Top linkage; the better long/short is USAR versus the broader unprofitable rare-earth basket, not versus a single project-specific name.

Key Decisions for Investors

• Tactically buy USAR on post-news weakness rather than chase strength; use a 1-3 month horizon and exit if the stock fails to hold the event-day breakout after funding-close details emerge.
• Set a watch item on USAR for Q3 funding completion and any update to 2026 commissioning; if either slips, reduce exposure because the stock is likely trading ahead of execution certainty.
• Pair trade: long USAR / short a basket of pre-revenue rare-earth developers on valuation discipline, because this deal improves USAR's strategic credibility while leaving weaker names exposed to dilution and project-timing risk.
• If market enthusiasm pushes USAR to a sharp rerating, consider selling upside via call spreads into that strength; the asymmetry is poor until there is visible oxide output and signed offtake.
• For higher-conviction risk control, treat TMRC as a relative loser if USAR captures downstream leverage from Round Top without needing near-term upstream monetization; monitor any TMRC-specific financing or project milestones as the thesis check.